Literature DB >> 6186366

Endotoxin-induced release of tumour necrosis factor and interferon in vivo is inhibited by prior adrenoceptor blockade.

N Bloksma, F Hofhuis, B Benaissa-Trouw, J Willers.   

Abstract

The effect of alpha- and beta-adrenoceptor blocking agents on endotoxin-induced release of tumour necrosis factor (TNF), and of interferon in the circulation of Corynebacterium parvum-treated mice was the subject of this study. TNF was quantified after injection of TNF containing heated serum (TNS) into Meth A sarcoma-bearing mice by determining colour, extent, and incidence of haemorrhagic necrosis. The release of TNF was weakly inhibited by the competitive alpha-blocker phentolamine and the beta-blocker propranolol. The non-competitive alpha-blocker phenoxybenzamine inhibited to a higher degree. Endotoxin-induced elicitation of growth-inhibiting principles into TNS was antagonized by propranolol and phenoxybenzamine. Administration of adrenaline before endotoxin inhibited the elicitation of TNF and growth-inhibitory activities, which indicates tachyphylaxis. The release of interferon was effectively inhibited by both alpha-adrenoceptor blockers but not by propranolol. The interferon was heat-labile. The results indicate that endotoxin-induced TNF and interferon are separate factors, elicited in different ways. As both alpha-blockers do not only inhibit reactions at the alpha-adrenergic receptor but also reactions at the serotonin receptor and in the case of phenoxybenzamine also at the choline receptor, it is suggested that endotoxin-induced release of the anti-tumour factors is controlled by reactions mediated by one or more of these receptors. It is suggested that the inhibition of TNF release by propranolol may be due to the membrane-stabilizing activity of this agent.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6186366     DOI: 10.1007/bf00199431

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  19 in total

1.  Cellular basis of interferon formation and hyporeactivity after exposure to bacterial lipopolysaccharide.

Authors:  M Ho; M C Breinig; N Maehara
Journal:  J Infect Dis       Date:  1976-06       Impact factor: 5.226

2.  Biological studies of interferon. I. Suppression of cellular infection with eastern equine encephalomyelitis virus.

Authors:  R R WAGNER
Journal:  Virology       Date:  1961-03       Impact factor: 3.616

3.  Effect of endotoxin on plasma catechol amines and serum serotonin.

Authors:  J C ROSENBERG; R C LILLEHEI; W H MORAN; B ZIMMERMANN
Journal:  Proc Soc Exp Biol Med       Date:  1959-11

4.  Production and properties of migration inhibitory factor and interferon in the circulation of mice with delayed hypersensitivity.

Authors:  J S Youngner; S B Salvin
Journal:  J Immunol       Date:  1973-12       Impact factor: 5.422

5.  The influence of vasoactive amines on interferon production in mice.

Authors:  M M Jensen
Journal:  Proc Soc Exp Biol Med       Date:  1969-01

6.  Effect of endotoxin on tumor resistance in mice.

Authors:  C Yang; A Nowotny
Journal:  Infect Immun       Date:  1974-01       Impact factor: 3.441

7.  In vitro and in vivo effects of endotoxin on mouse peritoneal cells.

Authors:  J W Shands; D L Peavy; B J Gormus; J McGraw
Journal:  Infect Immun       Date:  1974-01       Impact factor: 3.441

8.  Bone marrow colony-stimulating factor and tumor resistance-enhancing activity of postendotoxin mouse sera.

Authors:  R C Butler; A M Abdelnoor; A Nowotny
Journal:  Proc Natl Acad Sci U S A       Date:  1978-06       Impact factor: 11.205

9.  Functional and metabolic properties of polymorphonuclear leucocytes. II. The influence of a lipopolysaccharide endotoxin.

Authors:  Z A COHN; S I MORSE
Journal:  J Exp Med       Date:  1960-05-01       Impact factor: 14.307

10.  The immunological basis of endotoxin-induced tumor regression. Requirement for T-cell-mediated immunity.

Authors:  M J Berendt; R J North; D P Kirstein
Journal:  J Exp Med       Date:  1978-12-01       Impact factor: 14.307

View more
  6 in total

Review 1.  Vascular attack as a therapeutic strategy for cancer.

Authors:  J Denekamp
Journal:  Cancer Metastasis Rev       Date:  1990-11       Impact factor: 9.264

2.  Role of histamine in the antitumour activity of endotoxin.

Authors:  N Bloksma; P van de Wiel; F Hofhuis; F Kuper; J Willers
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

3.  Antitumour activity of endotoxin, concanavalin A and poly I: C and their ability to elicit tumour necrosis factor, cytostatic factors, and interferon in vivo.

Authors:  N Bloksma; C F Kuper; F M Hofhuis; B Benaissa-Trouw; J M Willers
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

4.  Synergistic action of human recombinant tumor necrosis factor with endotoxins or nontoxic poly A:U against solid Meth A tumors in mice.

Authors:  N Bloksma; F M Hofhuis
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

Review 5.  Phenoxybenzamine in complex regional pain syndrome: potential role and novel mechanisms.

Authors:  Mario A Inchiosa
Journal:  Anesthesiol Res Pract       Date:  2013-12-19

Review 6.  Tumour vasculature--a potential therapeutic target.

Authors:  C T Baillie; M C Winslet; N J Bradley
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.